According to a research report published this morning, Wedbush has decreased Illumina's ILMN PT from $65 to $52.
In the report, Wedbush commented, "With Roche out of the picture, we have reassessed our valuation framework. We are lowering our price target from $65 to $52, which assumes a 2012E EV/sales multiple of 5.5x versus our prior 7.5x multiple, which was based on the price Roche paid for Ventana in 2008. Additionally our $52 price target assumes a 2012E FCF yield of 4.6%, in line with the current diagnostics peer group median."
Wedbush maintains its Outperform rating on Illumina, which closed yesterday at $43.90.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in